The therapeutic spectrum of T2D and obesity therapy has recently been enriched by hybrid peptides acting as triple GLP-1R/GIPR/GCGR agonists that target both incretin and glucagon signalling to synergistically elicit favourable metabolic effects [225, 226]. Here, GCGR is linked to obesity due to melanocortin 4 receptor deficiency.